Pacific Edge Ltd
Company Profile
Business description
Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.
Contact
87 St David Street
P.O. Box 56
DunedinSTL9016
NZLT: +64 35776733
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2026
Employees
34
Stocks News & Analysis
stocks
For US software stocks, it’s been an AI bust, not a boom
stocks
Finding value in the Aussie mining sector
stocks
Strong start to the year for cheap ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,800.40 | 36.00 | 0.41% |
| CAC 40 | 7,959.67 | 21.40 | -0.27% |
| DAX 40 | 23,239.18 | 147.31 | 0.64% |
| Dow JONES (US) | 46,474.62 | 229.21 | 0.50% |
| FTSE 100 | 9,548.03 | 8.32 | 0.09% |
| HKSE | 25,716.50 | 496.48 | 1.97% |
| NASDAQ | 22,870.94 | 597.86 | 2.68% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,499.85 | 80.45 | 0.60% |
| S&P 500 | 6,707.15 | 104.16 | 1.58% |
| S&P/ASX 200 | 8,525.10 | 33.40 | 0.39% |
| SSE Composite Index | 3,836.77 | 1.87 | 0.05% |